Jefferies (NYSE:JEF) analyst Akash Tewari maintained a Hold rating on BioNTech SE (NASDAQ:BNTX) on Tuesday, setting a price target of $230, which is approximately 24.01% below the present share price of $302.69.
Tewari expects BioNTech SE to post earnings per share (EPS) of $13.24 for the fourth quarter of 2021.
The current consensus among 10 TipRanks analysts is for a Moderate Buy rating of shares in BioNTech SE, with an average price target of $294.5.
The analysts price targets range from a high of $400 to a low of $180.
In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $6.09 billion and a net profit of $4.56 billion. The company's market cap is $73.41 billion.
According to TipRanks.com, Jefferies analyst Akash Tewari is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 34.0% and a 50.00% success rate.
BioNTech SE is a Germany-based biotechnology company that develops and manufactures immunotherapies for cancer, infectious diseases, allergies and autoimmune disorders.